Inclisiran in Cardiovascular Health: A Review of Mechanisms, Efficacy, and Future Prospects

Abstract

Dyslipidemia is a significant risk factor for cardiovascular disease, and managing low-density lipoprotein cholesterol levels is a crucial strategy for both the prevention and treatment of cardiovascular disease. The active ingredient in the novel lipid-lowering drug, inclisiran, is a new type of small interfering RNA that primarily regulates blood lipid levels by inhibiting the synthesis of proprotein convertase subtilisin type 9 (PCSK9). Enhanced lipid-lowering effects can be achieved following 3 administrations. This article summarizes inclisiran’s mechanism of action, efficacy, safety, current research hotspots, clinical applications, and future development prospects, based on the latest literature and research advancements. Through comparative analysis with traditional lipid-lowering drugs, we conclude that inclisiran has promising application prospects and market potential, as it can complement traditional statin therapies to enhance lipid-lowering efficiency. This not only provides convenience to patients but also improves treatment compliance. Its safety profile alleviates patients’ concerns and mitigates the impact of negative emotions on their condition. Additionally, the potential applications of inclisiran in oncology have been identified. However, inclisiran also presents certain limitations and challenges. For instance, its long-term safety and efficacy require further investigation in future studies, and its high cost can restrict its widespread adoption and promotion. Furthermore, additional clinical evidence is needed to evaluate its synergistic or antagonistic effects when used in conjunction with other medications.